The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.
Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.
Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).
Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.
The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab.
Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.
The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."
Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.
John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.
Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.
Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.
Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.
John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.
Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.
Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.
Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.
Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.
Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.
Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.
Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.
Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.
Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.
Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.
Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.
Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.
After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.
Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.
